Advertisement for orthosearch.org.uk
Results 1 - 8 of 8
Results per page:
Orthopaedic Proceedings
Vol. 105-B, Issue SUPP_12 | Pages 43 - 43
23 Jun 2023
Carender CN Taunton MJ Fruth KM Pagnano MW Abdel MP
Full Access

There is a paucity of mid-term data on modular dual-mobility (MDM) constructs versus large (≥40 mm) femoral heads (LFH) in revision total hip arthroplasties (THAs). The purpose of this study was to update our prior series at 10 years, with specific emphasis on survivorships free of re-revision for dislocation, any re-revision, and dislocation. We identified 300 revision THAs performed at a single tertiary care academic institution from 2011 to 2014. Aseptic loosening of the acetabular component (n=65), dislocation (n=59), and reimplantation as part of a two-stage exchange protocol (n=57) were the most common reasons for index revision. Dual-mobility constructs were used in 124 cases, and LFH were used in 176 cases. Mean age was 66 years, mean BMI was 31 kg/m. 2. , and 45% were female. Mean follow-up was 7 years. The 10-year survivorship free of re-revision for dislocation was 97% in the MDM cohort and 91% in the LFH cohort with a significantly increased risk of re-revision for dislocation in the LFH cohort (HR 5.2; p=0.03). The 10-year survivorship free of any re-revision was 90% in the MDM cohort and 84% in the LFH cohort with a significantly increased risk of any re-revision in the LFH cohort (HR 2.5; p=0.04). The 10-year survivorship free of any dislocation was 92% in the MDM cohort and 87% in the LFH cohort. There was a trend towards an increased risk of any dislocation in the LFH cohort (HR 2.3; p=0.06). In this head-to-head comparison, revision THAs using MDM constructs had a significantly lower risk of re-revision for dislocation compared to LFH at 10 years. In addition, there was a trend towards lower risk of any dislocation. Level of Evidence: IV


Orthopaedic Proceedings
Vol. 106-B, Issue SUPP_16 | Pages 24 - 24
19 Aug 2024
Dagneaux L Abdel MP Sierra RJ Lewallen DG Trousdale RT Berry DJ
Full Access

Angular proximal femoral deformities increase the technical complexity of primary total hip arthroplasties (THAs). The goals were to determine the long-term implant survivorship, risk factors, complications, and clinical outcomes of contemporary primary THAs in this difficult cohort. Our institutional total joint registry was used to identify 119 primary THAs performed in 109 patients with an angular proximal femoral deformity between 1997 and 2017. The deformity was related to previous femoral osteotomy in 85%, and developmental or metabolic disorders in 15%. 53% had a predominantly varus angular deformity. The mean age was 44 years, mean BMI was 29 kg/m. 2. , and 59% were female. An uncemented metaphyseal fixation stem was used in 30%, an uncemented diaphyseal fixation stem in 28%, an uncemented modular body stem with metaphyseal fixation sleeve in 24%, and a cemented stem in 18%. Simultaneous corrective femoral osteotomy was performed in 18%. Kaplan-Meier survivorships and Harris hip scores were reported. Mean follow-up was 8 years. The 10-year survivorships free of femoral loosening, aseptic femoral revision, any revision, and any reoperation were 95%, 93%, 90% and 88%, respectively. Revisions occurred in 13 hips for: aseptic femoral component loosening (3), stem fracture (2), dislocation (2), aseptic acetabular loosening (2), polyethylene liner exchange (2), and infection (2). Preoperative varus angular deformities were associated with a higher risk of any revision (HR 10, p=0.03), and simultaneous osteotomies with a higher risk of any reoperation (HR 3.6, p=0.02). Mean Harris hip scores improved from 52 preoperatively to 82 at 10 years (p<0.001). In the largest series to date of primary THAs in patients with angular proximal femoral deformities, we found a good 10-year survivorship free from any revision. Varus angular deformities, particularly those treated with a simultaneous osteotomy due to the magnitude or location of the deformity, had a higher reoperation rate. Keywords: Proximal femoral deformity; dysplasia; femoral osteotomy; survivorship; revision. Level of evidence: Level III, comparative retrospective cohort


Orthopaedic Proceedings
Vol. 103-B, Issue SUPP_14 | Pages 1 - 1
1 Nov 2021
Mallett K Trousdale R Sierra R Abdel M Berry D
Full Access

Previous work has demonstrated increased implant failure in patients with DDH compared to osteoarthritis with historic methods and implants. This study examines outcomes of modern total hip arthroplasty (THA) techniques using uncemented fixation and cross-linked PE (XLPE) bearings for DDH. A consecutive series of 879 patients with DDH who underwent primary THA with uncemented components and a XLPE bearing at a single institution between 1999 and 2016 were identified. Mean age at index arthroplasty was 51 years, with 78% females. Mean follow-up was 8 years. 5- and 10-year survivorships free of revision were 98.4% and 98%, respectively. 5- and 10-year survivorships free of reoperation for any reason were 97% and 96%, respectively. Survivorship free of acetabular revision for aseptic loosening was 99.8% at 5 and 10 years, while survivorships free of femoral revision for aseptic loosening were 99.7% at 5 years and 99.5% at 10 years. Survivorship free of reoperation for PE damage (2 liner fractures, 2 rim damage from impingement) was 99.3% at 10 years. There were no revisions for bearing surface wear or osteolysis. 13% of patients experienced complications (4% dislocation, 3.3% wound complication rate). Ten-year survivorship free of reoperation for instability was 99.2%. 8 patients developed infection requiring operation (<1%). 100 patients had a prior pelvic osteotomy (11%), which did not increase rate of complications (p=0.22) or reoperations (p=0.51). Fixation with modern uncemented implants has dramatically reduced implant loosening in patients with DDH, and the use of XLPE bearings has markedly reduced revision for PE wear/osteolysis in this young patient population, leading to dramatically improved mid/long-term survivorship compared to historic series


Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_12 | Pages 36 - 36
1 Oct 2019
Bedard NA Brown TS Lewallen DG Trousdale RT Berry DJ Abdel MP
Full Access

Introduction. Many surgeons are reluctant to use a constrained liner at the time of acetabular component revision given concerns this might result in early acetabular component loosening. We hypothesized that with appropriate initial implant stabilization of highly porous acetabular components with supplemental screw fixation, constrained liners could be safely used at the time of acetabular revision. Methods. We retrospectively identified 148 revision total hip arthroplasties (THAs) where a constrained liner of one design was cemented into a newly placed highly porous acetabular component fixed with supplemental screws (mean 5 screws). Mean age at revision THA was 69 years, with 68% being female. The most common indications for revision were two-stage re-implantation (33%), recurrent dislocation (30%), and aseptic loosening (22% acetabular; 9% acetabular/femoral component). Mean follow-up was 8 years. Results. There were no failures at the bone-implant interface, and there were no revisions for aseptic loosening of the acetabular component. Furthermore, all acetabular components were bone ingrown on radiographic analysis. The 10-year survivorships free from any acetabular revision and free from any reoperation were 75% and 67%, respectively. Overall, 33 hips (22%) required revision or reoperation for infection/wound complications (n=12), dislocation (n=11), periprosthetic femur fracture (n=4), femoral loosening (n=3), and other (n=3). The 10-year survivorship free from dislocation was 84% overall, which was similar to the 85% 10-year survivorship free from dislocation for those specifically revised for instability (p=0.9). Conclusions. Implanting a constrained liner at the time of acetabular revision in high-risk patients resulted in no cases of aseptic acetabular component loosening in this large series. This is likely related to the fact that a highly porous acetabular component was utilized with a large number of supplemental screws in each case. Such information is valuable as these data favor a paradigm shift when compared to some traditionally-held tenets. For any tables or figures, please contact the authors directly


Orthopaedic Proceedings
Vol. 102-B, Issue SUPP_10 | Pages 20 - 20
1 Oct 2020
Engh CA Ho H Bhal V Housman LR Masonis JL Noble JW Hopper RH Su EP
Full Access

Introduction. The BIRMINGHAM HIP. ◊. Resurfacing is a metal-on-metal (MOM) hip implant system approved by the US FDA in 2006. The approval required a multicenter, prospective, post-approval study (PAS). Our purpose is to report the current minimum 10-year results. Methods. 253 patients (280 hips) had surgery between October 2006 and December 2009 at one of 5 sites. We report revisions, survivorship, EQ-5D, Harris Hip Score (HHS), radiographic findings, and metal levels including cobalt (Co) and chromium (Cr). The mean age at surgery was 51 years, 74% male, BMI 28, osteoarthritis 95%. 243 (87%) of hips have known outcome or 10-year minimum follow-up (fup). Prior to 10 years, 5 patients died, 20 hips were revised, and 37 hips did not complete 10-year fup. Results. The 10-year component survivorship is 92.9% (95% CI 89.8–96.1%). The reasons for revision were femoral neck fracture (3), femoral loosening (5), acetabular loosening (1), pseudotumor (3), osteolysis (2) and the remaining 6 for a combination of pain, noise, or metal levels. The EQ-QAL VAS improved (mean preop: 70, 1-year: 89, p<0.001) and was stable through 10 years (87, p=0.05). The HHS improved (mean preop: 57, 1-year: 96, p<0.001) and remained stable through 10 years (96, p=0.93). Radiographically, no surviving components have migrated. 4.6% (10/218) have osteolysis. The Co and Cr levels increased at 1 year (median Co preop: 0.12 ppb, 1-year: 1.5 ppb, p<0.001; Cr preop: 0.60 ppb, 1-year: 1.70 ppb, p<0.001) and remained stable through 10 years (Co 10-year: 1.29 ppb, p=0.28; Cr 10-year: 1.36 ppb, p=0.88). The number of patients with a Co or Cr >7 ppb at one and 10 years remained similar (1-year: 3.4% (7/205), 10-year: 4.4%, (9/205), p=0.61). Conclusion. This prospective, multicenter PAS demonstrated this resurfacing is safe and durable. 10-year survivorship for males less than 55 years old is 98.3% (95% CI 95.9–100%)


Orthopaedic Proceedings
Vol. 103-B, Issue SUPP_14 | Pages 3 - 3
1 Nov 2021
Manktelow A
Full Access

The clinical success of THA is accepted, however wide variation in implant usage and outcomes is reported across the world. The Getting It Right First Time initiative in the UK has recommended increased use of cemented constructs in patients over 70. A clear clinical directive has been proposed aiming to reduce revision rates, improve outcomes and increase cost effectiveness. This study compares the outcomes of cemented, hybrid and cementless THA from a high-volume single center at long-term follow-up. A prospective database identified 1,699 cemented, 5,782 hybrid and 2,631 cementless THAs. Mean follow-up was 8.1 years, 5.3 years and 6.3 years respectively. Primary endpoint was revision for any reason. 47 (1.79%) cemented, 93 (1.60%) hybrid and 39 (1.48%) cementless THAs underwent revision. The difference in overall revision rate was statistically significant (P=0.002). Mean time to revision was 4.5 years in the cemented group, 2.1 years in the hybrid group and 2.6 years in the cementless group. 1 year survivorship was 99.2% in the cemented group, 99.0% in the hybrid group and 98.9% in the cementless group. 3 year survivorship was 98.6% in the cemented group, 98.8% in the hybrid group and 98.9% in the cementless group. At 10 years it was 97.0%, 97.6% and 97.9% respectively. (Difference not statistically significant (p=0.09). Of relevance cemented fixation showed the lowest 10-year survivorship in patients over 70, over 75 and over 80. (not statistically significant P=0.5, 0.6 and 0.47 respectively). In a high-volume center, excellent outcomes were achieved at 10 years with all three constructs. Cemented THA had the lowest survivorship compared to hybrid, then cementless fixation. Cemented fixation did not outperform cementless fixation in any age group. Surgeons should monitor their outcomes. Use of a philosophy that works best in their own hands should be supported


Orthopaedic Proceedings
Vol. 102-B, Issue SUPP_10 | Pages 3 - 3
1 Oct 2020
Wellings EP Couch CG Taunton MJ Pagnano MW Berry DJ Abdel MP
Full Access

Introduction. Patients undergoing primary total hip arthroplasty (THA) following pelvic radiation have historically had poor survivorship free of aseptic acetabular component loosening. However, several series have reported improved results with tantalum acetabular components. The purpose of this study was to assess implant survivorship, radiographic results, and clinical outcomes of contemporary, non-tantalum, porous acetabular components in the setting of prior pelvic radiation. Methods. We retrospectively reviewed 33 patients (38 hips) with prior therapeutic pelvic radiation between 2006 and 2016 who underwent primary THA. The mean overall pelvic radiation dose was 6300 cGy with a mean latency period to THA of 5 years. The most common acetabular component was Pinnacle (Depuy-Synthes) in 76%, followed by Trident (Stryker) in 8%, Tritanium (Stryker) in 8%, Trilogy (Zimmer-Biomet) in 5%, and G7 (Zimmer-Biomet) in 3%. Eighty-seven percent of cups were fixed with screws, of which the mean number used was 3. The mean age at primary THA was 74 years, 76% were male, and the mean BMI was 30 kg/m. 2. Mean follow-up was 5 years. Results. The 10-year survivorship free of revision for aseptic loosening, free of any revision, and free of any reoperation were 100%, 89%, and 89%, respectively. There were three revisions; one each for taper corrosion, recurrent dislocation, and infection. Radiographically, all cups had evidence of osteointegration and none had radiographic evidence of loosening. The mean Harris hip score improved from 50 to 84 postoperatively (p<0.0001). Conclusion. Contemporary non-tantalum porous acetabular components with supplemental screws provided excellent implant fixation in patients with prior therapeutic pelvic radiation. At 10 years, 100% of these components were free of revision for aseptic loosening and 100% were radiographically well-fixed. Summary. Contemporary non-tantalum porous uncemented acetabular cups provided 100% survivorship free from revision for aseptic loosening for patients undergoing THA following therapeutic pelvic radiation


Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_4 | Pages 25 - 25
1 Apr 2022
Evans J Salar O Whitehouse S Kassam A Howell J Wilson M Timperley J Sayers A Whitehouse M Wilton T Hubble M
Full Access

The Exeter V40 femoral stem is the most implanted stem in the NJR for primary THA. In 2004, the 44/00/125 stem was released for use in “cement-in-cement” revision cases. It has however been used ‘off-label’ as a primary stem when, for example, patient anatomy requires a smaller stem with a 44mm offset. We aimed to investigate survival of this stem in comparison to others in the range when used in primary THAs recorded in the NJR. Analyses were performed using a dataset based on that used for the 2020 NJR annual report. Our exposure was the stem; the outcome was all-cause construct revision. Crude analyses were performed using Kaplan-Meier and adjusted using Cox models. The 44/00/125 stem was directly compared to other stems in the Exeter range. We analysed 330,732 primary THAs using the Exeter V40 stem comprising 34.5% of the 958,869 THAs with complete information from the start of the NJR to 31 December 2018. The 44/00/125 stem was implanted in 2,158 primary THAs with 67.5% in female patients and a mean age of 67.8. The 10-year revision estimate for the 44/00/125 stem was 4.9% (95%CI 3.6, 6.8) and in constructs using an Exeter V40 stem was 2.8% (95%CI 2.7, 2.8). Controlling for age, sex and ASA demonstrated an increased overall hazard of revision for constructs using the 44/00/125 stem compared to constructs using other Exeter V40 femoral stems (HR 1.8 (95%CI 1.4, 2.3)). Although the revision estimate is within the NICE 10-year benchmark, survivorship of constructs using the 44/00/125 stem appears to be lower than the rest of the Exeter V40 range. Attempts to control for age, sex and ASA will not take into account confounding by indication i.e. patients with more complex anatomy who may have a higher risk of revision. Surgeons and patients should be reassured by this but should be aware of the observed increased revision estimate and use the stem according to its indications